How Does Autolus Therapeutics plc (AUTL) Stack Up For Investors?

On Tuesday, shares of Autolus Therapeutics plc (NASDAQ:AUTL) marked $12.79 per share versus a previous $11.98 closing price. With having a 6.76% gain, an insight into the fundamental values of Autolus Therapeutics plc, investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. AUTL showed a fall of -3.11% within its YTD performance, with highs and lows between $3.00 – $20.85 during the period of 52 weeks, compared to the simple moving average of 16.77% in the period of the last 200 days.

Mizuho equity researchers changed the status of Autolus Therapeutics plc (NASDAQ: AUTL) shares to a “Buy” rating in the report published on April 22nd, 2020. Other analysts, including Needham, also published their reports on AUTL shares. Needham repeated the rating from the previous report, marking AUTL under “Buy” rating, in the report published on September 23rd, 2019. Additionally, AUTL shares got another “Buy” rating from H.C. Wainwright, setting a target price of $41 on the company’s shares, according to the report published in May 17th, 2019. On October 24th, 2018, H.C. Wainwright Initiated an Buy rating and increased its price target to $45.

Autolus Therapeutics plc (AUTL) Analysis

The present dividend yield for AUTL owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording , hinting the company’s progress in the upcoming progress.

In order to gain a clear insight on the performance of Autolus Therapeutics plc (AUTL) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 10.00 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.

Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while AUTL is currently recording an average of 149.35K in volumes. The volatility of the stock on monthly basis is set at 8.15%, while the weekly volatility levels are marked at 8.33%with 6.49% of gain in the last seven days.

What to Look for When Analyzing Autolus Therapeutics plc Shares?

Autolus Therapeutics plc (AUTL) is based in the United Kingdom and it represents one of the well-known company operating with Healthcare sector. If you wish to compare AUTL shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for Autolus Therapeutics plc, while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -2.87 is supported by the yearly EPS growth of -448.30%.

Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 26.63%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 31.90% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.

Are Institutional Investors Increasing Stakes in AUTL Shares?

It appears that more than several institutional investors and hedge funds decided to increase stakes in AUTL in the recent period. That is how Capital Research & Management Co. now has an increase position in AUTL by 34.61% in the first quarter, owning 2.96 million shares of AUTL stocks, with the value of $27.84 million after the purchase of an additional 760,000 shares during the last quarter. In the meanwhile, Schroder Investment Management Lt also increased their stake in AUTL shares changed 0.00% in the first quarter, which means that the company now owns 2.1 million shares of company, all valued at $19.74 million after the acquisition of additional 0 shares during the last quarter.

Woodford Investment Management Lt acquired a new position in Autolus Therapeutics plc during the first quarter, with the value of $19.74 million, and Polygon Global Partners LLP increased their stake in the company’s shares by 52.51% in the first quarter, now owning 682,601 shares valued at $18.68 million after the acquisition of the additional 1.98 million shares during the last quarter. In the end, Capital Research & Management Co. increased their position by 15.77% during the first quarter, now owning 1.22 million AUTL shares, now holding the value of $11.52 million in AUTL with the purchase of the additional 547,800 shares during the period of the last quarter. At the present, 31.90% of AUTL shares are in the ownership of institutional investors.